National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts.org
Search Results

From the 1/14/2022 release of VAERS data:

Found 3,619 cases where Vaccine is COVID19 and Symptom is COVID-19 and Patient Died

Government Disclaimer on use of this data



Case Details (Sorted by Age)

This is page 23 out of 362

Result pages: prev   14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32   next


VAERS ID: 1114057 (history)  
Form: Version 2.0  
Age:   
Sex: Male  
Location: Foreign  
Vaccinated:2021-02-05
Onset:2021-02-12
   Days after vaccination:7
Submitted: 0000-00-00
Entered: 2021-03-19
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EJ6788 / 1 LA / OT

Administered by: Other       Purchased by: ?
Symptoms: COVID-19, SARS-CoV-2 test
SMQs:, Infective pneumonia (broad), Opportunistic infections (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-02-12
   Days after onset: 0
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Acute on chronic renal failure; Cold type hemolytic anemia; Deep vein thrombosis (bilateral); Diabetes mellitus insulin-dependent; Obesity
Allergies:
Diagnostic Lab Data: Test Date: 20210121; Test Name: Covid-19 test; Test Result: Negative ; Test Date: 20210212; Test Name: Covid-19 PCR test; Result Unstructured Data: Test Result:highly positive; Comments: PCR
CDC Split Type: FRPFIZER INC2021272321

Write-up: COVID-19 respiratory infection; This is a spontaneous report from a contactable pharmacist downloaded from the Agency Regulatory Authority-WEB. This is a report received from the Agency, Regulatory authority report number FR-AFSSAPS-RE20210613. An 81-year-old male patient received his first dose of bnt162b2 (COMIRNATY), intramuscular, administered in Arm Left on 05Feb2021 (Lot Number: EJ6788) as single dose for covid-19 immunisation. Medical history included acute on chronic renal failure from Nov2020 to an unknown date, Diabetes mellitus insulin-dependent from an unknown date and unknown if ongoing, Cold type auto-immune hemolytic anemia from an unknown date and unknown if ongoing, obesity from an unknown date and unknown if ongoing, bilateral deep vein thrombosis from Jan2021 to an unknown date. Long-standing treatment included anticoagulant (unspecified). The patient experienced covid-19 respiratory infection with fatal outcome on 12Feb2021. Course of the event: On 21Jan2021, a test was performed and turned out to be negative. On 05Feb2021, the patient received a first injection of bnt162b2. On 12Feb2021, it was reported "Highly positive PCR". The patient experienced an Apathetic confusional state, "respiratory distress could not be corrected". This was due to SARS-CoV-2 infection progression in context of multiple underlying pathologies, it was not an adverse event but a lack of efficacy a week after the injection of the vaccine. The patient was considered at risk of developing a severe form of the disease "because of his medical history". The patient died on 12Feb2021. It was not reported if an autopsy was performed. No FU attempts possible. No further information expected.; Reported Cause(s) of Death: COVID-19 respiratory infection


VAERS ID: 1114593 (history)  
Form: Version 2.0  
Age:   
Sex: Male  
Location: Foreign  
Vaccinated:2021-01-01
Onset:2021-02-01
   Days after vaccination:31
Submitted: 0000-00-00
Entered: 2021-03-19
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EK9788 / 2 - / OT

Administered by: Other       Purchased by: ?
Symptoms: COVID-19, Death, General physical health deterioration, Respiratory failure, SARS-CoV-2 test, Vaccination failure
SMQs:, Anaphylactic reaction (broad), Lack of efficacy/effect (narrow), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (broad), Torsade de pointes, shock-associated conditions (broad), Hypovolaemic shock conditions (broad), Toxic-septic shock conditions (broad), Anaphylactic/anaphylactoid shock conditions (broad), Hypoglycaemic and neurogenic shock conditions (broad), Acute central respiratory depression (narrow), Guillain-Barre syndrome (broad), Hypersensitivity (broad), Respiratory failure (narrow), Infective pneumonia (broad), Hypokalaemia (broad), Opportunistic infections (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-02-10
   Days after onset: 9
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness: Arterial hypertension; Dementia; Diabetes mellitus; Multiple vessel coronary artery disease
Preexisting Conditions: Medical History/Concurrent Conditions: Adipositas
Allergies:
Diagnostic Lab Data: Test Date: 20210205; Test Name: COVID-19 virus test; Test Result: Positive ; Comments: 10 days after second Vaccination.
CDC Split Type: DEPFIZER INC2021266978

Write-up: Rapid deterioration of general condition; resp. Insufficiency; Unknown cause of death; COVID-19 confirmed by positive COVID-19 test; COVID-19 confirmed by positive COVID-19 test; This is a spontaneous report from a non-contactable consumer downloaded from the Agency Regulatory Authority-WEB with regulatory authority number DE-PEI-CADR2021016372. A 69-year-old male patient received the first dose of BNT162B2 (COMIRNATY), via unknown route of administration on 31Dec2020 at single dose, and received the second dose of BNT162B2, intramuscularly in Jan2021 (Lot Number: EK9788) at single dose, both for COVID-19 immunisation. Medical history included ongoing diabetes mellitus, ongoing arterial hypertension, ongoing dementia, ongoing multiple vessel coronary artery disease, and adipositas. The patient''s concomitant medications were not reported. It was reported ''10 days after second vaccination positive test to Covid 19. Rapid deterioration of general condition and resp. Insufficiency in Feb2021, Hospitalization, ventilation there, died on 10Feb2021''. The patient experienced unknown cause of death on 10Feb2021 and Positive test to Covid 19 on 05Feb2021. The patient underwent lab tests and procedures which included SARS-COV-2 test: positive on 05Feb2021 (also reported as 10 days after second Vaccination). Therapeutic measures were taken as a result of respiratory insufficiency included treatment with ventilation. The outcome of events ''COVID-19 confirmed by positive COVID-19 test'' was not resolved, of events ''Rapid deterioration of general condition'' and ''resp. Insufficiency'' was unknown. The patient died on 10Feb2021. It was not reported if an autopsy was performed. No follow-up attempts needed, follow-up automatically provided by Regulatory Authority.; Reported Cause(s) of Death: Unknown cause of death


VAERS ID: 1121390 (history)  
Form: Version 2.0  
Age:   
Sex: Female  
Location: Foreign  
Vaccinated:2021-01-29
Onset:2021-02-01
   Days after vaccination:3
Submitted: 0000-00-00
Entered: 2021-03-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EJ6788 / 1 - / OT

Administered by: Other       Purchased by: ?
Symptoms: Alanine aminotransferase, Aspartate aminotransferase, Asthenia, Bacterial pyelonephritis, Blood bicarbonate, Blood creatinine, Blood potassium, Blood sodium, C-reactive protein, COVID-19, COVID-19 pneumonia, Chills, Coma scale, Computerised tomogram, Cough, Culture urine, General physical health deterioration, Haemoglobin, Klebsiella infection, Liver function test, Microscopy, Oedema peripheral, Physical examination, Platelet count, Pyrexia, SARS-CoV-2 test, Sepsis, Urine analysis, White blood cell count
SMQs:, Cardiac failure (broad), Anaphylactic reaction (broad), Angioedema (broad), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Guillain-Barre syndrome (broad), Haemodynamic oedema, effusions and fluid overload (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Infective pneumonia (narrow), Sepsis (narrow), Opportunistic infections (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-02-17
   Days after onset: 16
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: BISOPROLOL; ATORVASTATIN; DEPAKOTE; RISPERIDONE; FUROSEMIDE; CANDESARTAN CILEXETIL; RENVELA; LYRIC [PREGABALIN]; MELAXOSE; MIMPARA; LAMALINE [CAFFEINE;PAPAVER SOMNIFERUM LATEX;PARACETAMOL]; NOVORAPID; ABASAGLAR; KARDEGIC; PANTOPRAZOLE; CALC
Current Illness: Chronic renal failure
Preexisting Conditions: Medical History/Concurrent Conditions: Anaemia; Arterial hypertension; Atrioventricular block; Bipolar disorder; Cardiorenal syndrome; Congestive heart failure; Diabetic nephropathy; Heart block atrioventricular; Heart disease, unspecified (with conserved fraction of ejection); Hemodialysis; Hyperparathyroidism secondary; Hyperuricemia; Nephroangiosclerosis; Obesity; Sleep apnea syndrome; Type 2 diabetes mellitus
Allergies:
Diagnostic Lab Data: Test Date: 20210211; Test Name: ALT; Result Unstructured Data: Test Result:195; Comments: increased; Test Date: 20210211; Test Name: AST; Result Unstructured Data: Test Result:250; Comments: increased; Test Date: 20210205; Test Name: bicarbonates; Result Unstructured Data: Test Result:28 mmol/L; Test Date: 20210205; Test Name: creatinine; Result Unstructured Data: Test Result:194 umol/l; Test Date: 20210211; Test Name: creatinine; Result Unstructured Data: Test Result:544 umol/l; Test Date: 20210205; Test Name: potassium; Result Unstructured Data: Test Result:3.2 mmol/L; Test Date: 20210205; Test Name: sodium; Result Unstructured Data: Test Result:139 mmol/L; Test Date: 202102; Test Name: Glasgow score; Result Unstructured Data: Test Result:15; Test Date: 202102; Test Name: thoracic CT; Result Unstructured Data: Test Result:compatible aspect with SARS-cov-2 pneumonia; Comments: with multiple focus of superinfection of pneumonic appearance; Test Date: 20210205; Test Name: C-reactive protein; Result Unstructured Data: Test Result:27 mg/l; Test Date: 202102; Test Name: culture of urine; Result Unstructured Data: Test Result:disclosed infection to Klebsiella Pneumoniae exten; Comments: disclosed infection to Klebsiella Pneumoniae extended-spectrum beta-lactamases; Test Date: 20210205; Test Name: hemoglobin; Result Unstructured Data: Test Result:100 g/l; Test Date: 20210211; Test Name: hemoglobin; Result Unstructured Data: Test Result:87 g/l; Test Date: 20210205; Test Name: liver function; Result Unstructured Data: Test Result:normal; Test Date: 202102; Test Name: microscopy; Result Unstructured Data: Test Result:disclosed infection to Klebsiella Pneumoniae exten; Comments: disclosed infection to Klebsiella Pneumoniae extended-spectrum beta-lactamases; Test Date: 202102; Test Name: cardiac examination; Result Unstructured Data: Test Result:no unusual sign; Test Date: 20210205; Test Name: platelets; Result Unstructured Data: Test Result:152 x10 9/l; Test Date: 20210211; Test Name: platelets; Result Unstructured Data: Test Result:132 x10 9/l; Test Date: 20210206; Test Name: SARS-CoV-2 PCR test; Test Result: Positive ; Test Date: 202102; Test Name: culture of urine; Result Unstructured Data: Test Result:infection to Klebsielle Pneumoniae; Test Date: 20210205; Test Name: white blood cells; Result Unstructured Data: Test Result:6 x10 9/l; Test Date: 20210211; Test Name: white blood cells; Result Unstructured Data: Test Result:5.2 x10 9/l
CDC Split Type: FRPFIZER INC2021272353

Write-up: general and respiratory condition deterioration; SARS-CoV-2 (RT-PCR) was positive/COVID-19 aggravated; discreet edema of lower limbs; chills; light dry cough; fever; pneumonia to SARS-Cov-2; bacterial pyelonephritis; infection to Klebsiella Pneumoniae extended-spectrum beta-lactamases; important septic state; important asthenia; This is a spontaneous report from a contactable pharmacist downloaded from the WEB FR-AFSSAPS-LY20211184. A 73-year-old female patient received first dose of bnt162b2 (COMIRNATY), intramuscular on 29Jan2021 (Batch/Lot Number: EJ6788) at single dose for COVID-19 vaccination. Medical history included heart block atrioventricular, anemia, arterial hypertension, type 2 diabetes mellitus, hyperparathyroidism secondary, ongoing chronic renal failure associated with diabetic nephropathy, obesity, bipolar disorder, sleep apnea syndrome, hyperuricemia, nephroangiosclerosis, cardio-renal syndrome, with hemodialysis initiated on 10Apr2019, heart disease with conserved fraction of ejection with multiple episodes of congestive heart failure, atrioventricular block with pacemaker. SARS-Cov-2 history was unknown. Concomitant medications included bisoprolol, atorvastatin, valproate semisodium (DEPAKOTE), risperidone, furosemide, candesartan cilexetil, sevelamer carbonate (RENVELA), pregabalin (LYRIC), lactulose, paraffin, liquid (MELAXOSE), cinacalcet hydrochloride (MIMPARA), caffeine, papaver somniferum latex, paracetamol (LAMALINE), insulin aspart (NOVORAPID), insulin glargine (ABASAGLAR), acetylsalicylate lysine (KARDEGIC), pantoprazole, calcium carbonate (CALCIDOSE), zopiclone (IMOVANE), sodium polystyrene sulfonate (KAYEXALATE). On 29Jan2021 patient received a first injection of COVID-19 mRNA Vaccine (nucleoside modified) (COMIRNATY) for vaccination against SARS-COV-2. On 03Feb2021 patient felt after dialysis. On 05Feb2021 patient experienced chills, but no fever, with light dry cough not noticed before. Hemodynamic state was stable. No clinical evidence of infection was observed, no dysuria, no bowel disorder. No unusual sign on cardiac examination, but discreet edema of lower limbs. No clinical evidence of pneumonia. No bowel disorder. The patient presented with important asthenia, but Glasgow score was 15. Antibiotics by ceftriaxone sodium (unspecified trade name) and gentamicin (unspecified trade name) were started. On 06Feb2021 SARS-CoV-2 reverse transcriptase-polymerase chain reaction (RT-PCR) was positive. Later, pulmonary condition decreased with wheezing and crackles in bases, requiring oxygen therapy. Direct microscopy and culture of urine disclosed infection to Klebsiella Pneumoniae extended-spectrum beta-lactamases, requiring a treatment by imipenem (unspecified trade name) 500mg twice daily. In Feb2021, the patient presented with important septic state with unwell tolerated fever, and covid-19 aggravated. On 16Feb2021 due to general and respiratory condition deterioration it was decided to stop active treatments and to continue comfort care. Patient died on 17Feb2021. In total: complications of pneumonia to SARS-Cov-2 with (bacterial) pyelonephritis to Klebsielle Pneumoniae extended-spectrum beta-lactamases. Laboratory work-up: On 05Feb2021: white blood cells 6 x10^9/L, heamoglobin 100 g/L, platelets 152 x10^9/L, sodium 139 mmol/L, potassium 3.2 mmol/L, bicarbonates 28 mmol/L, creatinine 194 umol/L (usual range not known), liver function was normal, C-reactive-protein 27 mg/L. On 11Feb2021: white blood cells 5.2 x10^9/L, hemoglobin 87 g/L, platelets 132 x10^9/L, creatinine 544 umol/L (usual range not known), increased transaminases (Aspartate aminotransferase 250 and alanine aminotransferase 195 normal ranges not available). Additional examination: In Feb2021 thoracic computed tomography disclosed compatible aspect with SARS-cov-2 pneumonia, with multiple focus of superinfection of pneumonic appearance. The patient died on 17Feb2021. Cause of death was bacterial pyelonephritis and COVID-19 pneumonitis, covid-19, infection to Klebsiella Pneumoniae extended-spectrum beta-lactamases and general and respiratory condition deterioration. It was not reported if an autopsy was performed. No follow-up attempts are possible. No further information is expected.; Reported Cause(s) of Death: infection to Klebsiella Pneumoniae extended-spectrum beta-lactamases; general and respiratory condition deterioration; SARS-CoV-2 (RT-PCR) was positive/COVID-19 aggravated; Bacterial pyelonephritis; COVID-19 pneumonitis


VAERS ID: 1121397 (history)  
Form: Version 2.0  
Age:   
Sex: Female  
Location: Foreign  
Vaccinated:2021-02-10
Onset:2021-02-18
   Days after vaccination:8
Submitted: 0000-00-00
Entered: 2021-03-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EJ6789 / 2 RA / OT

Administered by: Other       Purchased by: ?
Symptoms: COVID-19, Pyrexia, SARS-CoV-2 test positive, Vaccination failure
SMQs:, Lack of efficacy/effect (narrow), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Infective pneumonia (broad), Opportunistic infections (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-02-23
   Days after onset: 5
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Cardiac failure; Hypertension arterial
Allergies:
Diagnostic Lab Data: Test Date: 20210221; Test Name: fever; Result Unstructured Data: Test Result:39 Centigrade; Test Date: 20210218; Test Name: COVID-19 PCR test positive; Test Result: Positive
CDC Split Type: FRPFIZER INC2021283098

Write-up: COVID-19 with symptoms; COVID-19 PCR test positive; This is a spontaneous report from a contactable physician downloaded from the Regulatory Authority-WEB FR-AFSSAPS-PO20211154. A 93-years-old female patient received bnt162b2 (COMIRNATY) vaccine, dose 2 intramuscular, administered in Arm Right on 10Feb2021 (Batch/Lot Number: EJ6789) as 0.3 mL, single, dose 1 intramuscular on 20Jan2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation . Medical history included hypertension , cardiac failure. The patient''s concomitant medications were not reported. The patient experienced covid-19 PCR test positive on 18Feb2021 , covid-19 with symptoms on 21Feb2021: appearance of fever at 39 �C, cough, bronchial congestion and desaturation. Treated with 5 L O2 and antibiotic therapy. The patient underwent lab tests and procedures which included pyrexia: 39�C on 21Feb2021 , sars-cov-2 test positive on 18Feb2021. The patient died on 23Feb2021. It was not reported if an autopsy was performed. No follow-up attempts are possible. No further information is expected. Batch/lot number of the first dose cannot be obtained.; Reported Cause(s) of Death: Covid-19


VAERS ID: 1121578 (history)  
Form: Version 2.0  
Age:   
Sex: Male  
Location: Foreign  
Vaccinated:0000-00-00
Onset:2021-03-01
Submitted: 0000-00-00
Entered: 2021-03-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH UNKNOWN / 1 - / -

Administered by: Other       Purchased by: ?
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccination failure
SMQs:, Lack of efficacy/effect (narrow), Infective pneumonia (broad), Opportunistic infections (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-03-01
   Days after onset: 0
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Dementia; Diabetes; Myocardial infarct; Stroke
Allergies:
Diagnostic Lab Data: Test Date: 202103; Test Name: COVID 19 test; Test Result: Positive
CDC Split Type: SEPFIZER INC2021283335

Write-up: drug ineffective/diagnosed with Covid 13 days after vaccination of dose 2; COVID-19; This is a spontaneous report from a contactable physician downloaded from the Agency-WEB, regulatory authority number SE-MPA-2021-011683. Other Case identifier number: SE-MPA-1614952941111. An 87-year-old male patient received bnt162b2 (COMIRNATY), dose 2 intramuscular on an unknown date in Feb2021 (Batch/Lot Number: EL0725) as 0.3 mL, single; and dose 1 via an unspecified route of administration on an unspecified date (Batch/Lot Number: unknown) as a single dose for COVID-19 immunisation. Medical history included previous myocardial infarction, previous stroke, diabetes mellitus and dementia, all from an unknown date and unknown if ongoing. The patient''s concomitant medications were not reported. Reported suspect adverse event was death. The patient experienced death, covid-19 and drug ineffective. The patient was vaccinated at his nursing home with COMIRNATY dose 2 in February 2021. Then fell ill with Covid-19 on an unspecified date in Mar2021. He was diagnosed with Covid 13 days after vaccination of dose 2. He died in the aftermath of the disease in early March, three weeks after dose 2 of Comirnaty. Outcome: Fatal. Report assessed as serious, death. The patient underwent lab tests and procedures which included sars-cov-2 test positive: positive in Mar2021. The patient died on Mar2021. It was not reported if an autopsy was performed.; Reported Cause(s) of Death: COVID-19; drug ineffective/diagnosed with Covid 13 days after vaccination of dose 2


VAERS ID: 1122448 (history)  
Form: Version 2.0  
Age:   
Sex: Female  
Location: Foreign  
Vaccinated:2021-01-31
Onset:2021-02-05
   Days after vaccination:5
Submitted: 0000-00-00
Entered: 2021-03-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EN1185 / 1 - / -

Administered by: Other       Purchased by: ?
Symptoms: COVID-19, Cough, Neutropenia, Neutropenic sepsis, Neutrophil count, SARS-CoV-2 test
SMQs:, Anaphylactic reaction (broad), Agranulocytosis (narrow), Haematopoietic leukopenia (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Infective pneumonia (broad), Sepsis (narrow), Opportunistic infections (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-02-15
   Days after onset: 10
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications: ACICLOVIR; AMLODIPINE; CALCICHEW; CIPROFLOXACIN; CO-TRIMOXAZOLE; FLUCONAZOLE; HYLO-FORTE; METOCLOPRAMIDE; ONDANSETRON
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Acute lymphoblastic leukaemia; Acute myeloid leukemia; Leukaemia (replaced leukaemia); Neoplasm (Recently had treatment for cancer, leukaemia or lymphoma (radiotherapy or chemotherapy)); Neutropenic sepsis; Stem cell transplant (second stem cell transplant); Stem cell transplant
Allergies:
Diagnostic Lab Data: Test Name: Neutrophil count; Result Unstructured Data: Test Result:0.0; Test Date: 20210127; Test Name: SARS-CoV-2 test; Result Unstructured Data: Test Result:No, Negative COVID-19 test; Test Date: 20210205; Test Name: SARS-CoV-2 test; Test Result: Positive
CDC Split Type: GBPFIZER INC2021295175

Write-up: neutropenic sepsis; Neutropenia; cough; SARS-CoV-2 infection; This is a spontaneous report from a contactable consumer. This is a report received from the Regulatory Agency (RA). Regulatory authority report number GB-MHRA-WEBCOVID-202103150909596000, Safety Report Unique Identifier GB-MHRA-ADR 24942833. A 69-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 31Jan2021 (Batch/Lot Number EN1185) as single dose for covid-19 immunization. Medical history included neutropenic sepsis from an unknown date and unknown if ongoing, neoplasm from an unknown date and unknown if ongoing (Recently had treatment for cancer, leukemia or lymphoma; radiotherapy or chemotherapy), acute myeloid leukemia from Jan2016 to an unknown date, acute lymphocytic leukemia from Jan2016 to an unknown date, stem cell transplant from May2016 to an unknown date, leukemia from Jan2018 to an unknown date (replaced leukemia), stem cell transplant from May2018 to an unknown date (second stem cell transplant). Patient has not had symptoms associated with COVID-19. Patient is not enrolled in clinical trial. Concomitant medications included acyclovir taken for an unspecified indication, start and stop date were not reported; amlodipine taken for an unspecified indication, start and stop date were not reported, calcium carbonate (CALCICHEW) taken for an unspecified indication, start and stop date were not reported; ciprofloxacin taken for an unspecified indication, start and stop date were not reported, co-trimoxazole taken for an unspecified indication, start and stop date were not reported; fluconazole taken for an unspecified indication, start and stop date were not reported; hyaluronate sodium (HYLO-FORTE) taken for an unspecified indication, start and stop date were not reported; metoclopramide taken for an unspecified indication, start and stop date were not reported; ondansetron taken for an unspecified indication, start and stop date were not reported. Patient had relapsed AML receiving chemotherapy at home as part of palliative care package. Patient was shielded for 12 months with her husband. Intravenous nurses wearing full PPE were the only other contacts within the past 2 weeks, prior to that hematology appointment on 27Jan2021, again full PPE worn at all times. Patient was on day 5 of chemo when nurse measured temperature and recorded as 38.5C therefore sent to emergency on neutropenic pathway. Neutrophil count 0.0 at clinic and also on admission 05Feb2021. Swabbed positive in Emergency for COVID-19 same day. Admitted to hospital and treated for neutropenic sepsis. Developed a cough and increased Oxygen requirement, resulting in continuous positive airway pressure treatment 10Feb2021. The patient experienced sars-cov-2 infection (covid-19) (death) on 05Feb2021, neutropenic sepsis (neutropenic sepsis) (hospitalization, medically significant) on an unspecified date with outcome of unknown, neutropenia (neutropenia) (hospitalization, medically significant) on an unspecified date with outcome of unknown, cough (cough) (non-serious) on an unspecified date with outcome of unknown. The patient underwent lab tests and procedures which included sars-cov-2 test: no, negative covid-19 test on 27Jan2021 and positive on 05Feb2021, neutrophil count: 0.0 on an unspecified date. Therapeutic measures were taken as a result of neutropenic sepsis (neutropenic sepsis), cough (cough). The patient died on 15Feb2021. It was not reported if an autopsy was performed. Sadly died 15Feb2021 due to Covid-19. Patient had Covid PCR test and ongoing palliative treatment under joint care of MRI. Patient was fully shielded from Feb2020. No follow-up attempts are possible. No further information is expected.; Reported Cause(s) of Death: SARS-CoV-2 infection


VAERS ID: 1126490 (history)  
Form: Version 2.0  
Age:   
Sex: Male  
Location: Foreign  
Vaccinated:2021-02-01
Onset:2021-02-04
   Days after vaccination:3
Submitted: 0000-00-00
Entered: 2021-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EJ6788 / 1 LA / OT

Administered by: Other       Purchased by: ?
Symptoms: Alanine aminotransferase, Aspartate aminotransferase, Biliary tract infection, Blood alkaline phosphatase, Blood pressure measurement, C-reactive protein decreased, COVID-19, Cholecystitis, Computerised tomogram, Computerised tomogram thorax, Gamma-glutamyltransferase, Heart rate, Hypokalaemia, Oxygen saturation, Pyrexia, Respiratory rate, SARS-CoV-2 test positive
SMQs:, Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Infectious biliary disorders (narrow), Gallbladder related disorders (narrow), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Infective pneumonia (broad), Hypokalaemia (narrow), Opportunistic infections (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-02-22
   Days after onset: 18
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: POLYIONIQUE G5; MOVICOL PLAIN; ATORVASTATIN; LOVENOX [ENOXAPARIN SODIUM]; KARDEGIC; FUROSEMIDE
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Cholangitis; Dyslipidaemia; Femur fracture; Hypertension arterial; Myocardial infarction; Stroke
Allergies:
Diagnostic Lab Data: Test Date: 20210205; Test Name: ALAT; Result Unstructured Data: Test Result:221 IU/l; Test Date: 20210205; Test Name: ASAT; Result Unstructured Data: Test Result:201 IU/l; Test Date: 20210215; Test Name: biliary sample for Citrobacter Freundii; Result Unstructured Data: Test Result:positive for Citrobacter Freundii; Test Date: 20210205; Test Name: PAL; Result Unstructured Data: Test Result:316 IU/l; Test Date: 20210208; Test Name: blood pressure; Result Unstructured Data: Test Result:158/86 mmHg; Test Date: 20210209; Test Name: Thoraco-abdomino-pelvic CT scan; Result Unstructured Data: Test Result:Sub-optimal quality injection that does not; Comments: Sub-optimal quality injection that does not allow formal pulmonary embolism to be eliminated. No embolus detected up to the lobe level. - Aggravation of bilateral frosted glass areas, compatible with Covid, involving 30 to 50% of the pulmonary parenchyma. - We find the appearance of cholecystitis, with an overall irregular and laminated wall, with probable rupture of the vesicular fundus seeming to communicate with a small collection coming into contact with the right colic angle just under the abdominal wall. Interest of a surgical opinion.; Test Date: 20210204; Test Name: thoracic CT; Result Unstructured Data: Test Result:the low sections a possible vesicular wall thicken; Comments: the low sections a possible vesicular wall thickening with lithiasis at the neck and infiltration to be confronted at the clinic; Test Date: 20210208; Test Name: CRP; Result Unstructured Data: Test Result:57.1 mg/l; Test Date: 20210205; Test Name: GGT; Result Unstructured Data: Test Result:734 IU/l; Test Date: 20210208; Test Name: Heart rate; Result Unstructured Data: Test Result:78 bpm; Test Name: hypokalaemia; Result Unstructured Data: Test Result:3 mmol/L; Test Date: 20210208; Test Name: saturation; Test Result: 92 %; Comments: under 2L of O2; Test Date: 20210208; Test Name: fever; Result Unstructured Data: Test Result:38.1 Centigrade; Test Date: 20210208; Test Name: respiratory rate; Result Unstructured Data: Test Result:28/min; Test Date: 20210204; Test Name: COVID-19 PCR test positive; Test Result: Positive ; Comments: 3 days after the first dose of COMIRNATY
CDC Split Type: FRPFIZER INC2021283163

Write-up: COVID PCR coming back positive/Sars-Cov2 infection; Cholecystitis; This is a spontaneous report from a contactable physician from the regulatory authority FR-AFSSAPS-RS20210385. An 87-year-old male patient received first dose of bnt162b2 (COMIRNATY), intramuscular in arm left on 01Feb2021 (Lot Number: EJ6788) as single dose for COVID-19 immunization. Medical history included cholangitis from 2020, myocardial infarction from 2011, Dyslipidaemia, Hypertension arterial, femoral fracture (Patient hospitalized in follow-up and rehabilitation care since 08Dec following surgery on a femoral fracture), stroke from 2006. Concomitant medications included glucose, potassium chloride, sodium chloride (POLYIONIQUE G5, 5% 1L/24h); macrogol 3350, potassium chloride, sodium bicarbonate, sodium chloride (MOVICOL PLAIN, reported as Movicol 1 sachet / day); atorvastatin; enoxaparin sodium (LOVENOX); acetylsalicylate lysine (KARDEGIC); furosemide. The patient experienced COVID PCR coming back positive/Sars-Cov2 infection complicated by cholecystitis on 04Feb2021. 01Feb2021: Vaccination with bnt162b2 in the left arm (first dose). 04Feb2021: in front of a fever and oxygen refereeing, realization of a COVID PCR coming back positive. This Sars-cov2 infection is complicated by cholecystitis (presence of a Murphy sign). The thoracic scanner found in the low sections a possible vesicular wall thickening with lithiasis at the neck and infiltration to be confronted at the clinic. The opinion with the radiologist finds a peri-vesicular effusion. Cholecystitis is treated with Ceftriaxone and metronidazole (FLAGYL) from 04Feb2021 in the evening. 05Feb2021: evidence of cytolysis (ASAT 201 IU / L, ALAT 221 IU/ L) as well as anicteric cholestasis ( phosphatases alcalines (PAL) 316 IU / L, G-GT at 734 IU / L). Biological inflammatory syndrome decreasing with the last CRP of 08Feb2021 at 57.1 mg / L. In terms of Covid, the patient is on 2L of O2 without the need for dexamethasone for the moment. Transfer on 08Feb2021 for close monitoring Upon entering the service: Physical examination: Aware and Oriented, Glasgow 15, BP 158/86 mmHg, heart rate 78 bpm, Fever at 38.1 degrees C, 92% saturation under 2L of O2 with a respiratory rate of 28 / min, no draft, no cyanosis. His pulmonary auscultation found a bilateral and symmetrical vesicular murmur without added noise. His cardiac auscultation found regular heart sounds without a perceived breath. His abdominal examination found a supple, depressible and painless abdomen without pain at the epigastric level or in the right hypochondrium. He shows no resistance, no contracture, no Murphy sign. Evolution: Respiratory worsening with the need for the introduction of 8L of O2 associated with increased polypnea; introduction of corticosteroid therapy with dexamethasone from 09Feb2021 to 17Feb2021. 09Feb2021: Thoraco-abdomino-pelvic CT scan (to look for pulmonary embolism and abdominal cuts to look for an abdominal infectious focus in this context of suspected cholecystitis). Sub-optimal quality injection that does not allow formal pulmonary embolism to be eliminated. No embolus detected up to the lobe level. Aggravation of bilateral frosted glass areas, compatible with Covid, involving 30 to 50% of the pulmonary parenchyma. It was found that the appearance of cholecystitis, with an overall irregular and laminated wall, with probable rupture of the vesicular fundus seeming to communicate with a small collection coming into contact with the right colic angle just under the abdominal wall. Interest of a surgical opinion. An opinion from digestive surgeons was taken proposing the following management: continuation of inpatient monitoring; continuation of antibiotic therapy with ceftriaxone and Flagyl and performance of radiological cholecystostomy. An 8.5F drain was therefore placed in the gallbladder. 12Feb2021: respiratory worsening; oxygen therapy at 15L with a high concentration mask and increase in the dose of furosemide to 250 mg / day. 15Feb2021: The biliary sample during drainage by radiological cholecystostomy returned positive for Citrobacter Freundii, the antibiotic treatment is switched by cefepime 2g morning and evening for 5 days. Biologically, the patient presents hypokalaemia at 3 mmol / L without any sign of ECG, requiring supplementation with Diffu-K. During hospitalization serum potassium gradually normalized. 17Feb2021: Introduction of Midazolam 0.1 mg / h h intravenous via infusion pump + Morphine 0.5 mg / h intravenous via infusion pump in front of the discomfort and the non-regression of the severity of the COVID infection. Increase on 21Feb2021 of Midazolam to 0.2 mg / h and Morphine to 1 mg / h. 22Feb2021: death of the patient noted. In total: PCR Sars cov2 positive 3 days after the first dose of COMIRNATY. Patient died of severe Sars-Cov2 infection, complicated by cholecystitis. It was not reported if an autopsy was performed. No follow-up attempts are possible. No further information is expected. ; Reported Cause(s) of Death: COVID PCR coming back positive/Sars-Cov2 infection; Cholecystitis


VAERS ID: 1132239 (history)  
Form: Version 2.0  
Age:   
Sex: Female  
Location: Foreign  
Vaccinated:2020-12-23
Onset:2021-01-07
   Days after vaccination:15
Submitted: 0000-00-00
Entered: 2021-03-25
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH - / 1 - / -

Administered by: Other       Purchased by: ?
Symptoms: COVID-19, Drug ineffective, Dyspnoea, SARS-CoV-2 test
SMQs:, Anaphylactic reaction (broad), Lack of efficacy/effect (narrow), Acute central respiratory depression (broad), Pulmonary hypertension (broad), Cardiomyopathy (broad), Infective pneumonia (broad), Opportunistic infections (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-01-23
   Days after onset: 16
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications: INFLUENZA VIRUS
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Test Date: 20210108; Test Name: COVID-19 virus test; Test Result: Positive
CDC Split Type: GBPFIZER INC2021290306

Write-up: SARS-CoV-2 infection; SARS-CoV-2 infection; Labored breathing; This is a spontaneous report from a contactable consumer. This is a report received from the regulatory authority. Regulatory authority report number GB-MHRA-WEBCOVID-202103130818077010 and GB-MHRA-ADR 24931770. A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; Solution for injection; Lot number: not reported), via an unspecified route of administration on 23Dec2020 at single dose for COVID-19 immunization. Concomitant medication included influenza vaccine (INFLUENZA VIRUS) taken for influenza immunisation. The patient experienced labored breathing on 07Jan2021 and SARS-COV-2 infection on 08Jan2021. The patient died on 23Jan2021 due to SARS-COV-2 infection. It was not reported if an autopsy was performed. The outcome of the event SARS-CoV-2 infection was reported as fatal, whereas unknown for another event. No follow-up attempts are possible; information about lot/batch number cannot be obtained. Amendment: This follow up is being submitted to amend previously reported information: Updated labelling for the events "Drug ineffective, SARS-CoV-2 infection and Labored breathing" from listed to unlisted.; Reported Cause(s) of Death: SARS-CoV-2 infection; SARS-CoV-2 infection


VAERS ID: 1132474 (history)  
Form: Version 2.0  
Age:   
Sex: Male  
Location: Foreign  
Vaccinated:2021-02-19
Onset:2021-03-05
   Days after vaccination:14
Submitted: 0000-00-00
Entered: 2021-03-25
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EP9598 / 1 - / -

Administered by: Other       Purchased by: ?
Symptoms: COVID-19, Death, Drug ineffective, Dyspnoea, Oxygen saturation, Pyrexia, SARS-CoV-1 test
SMQs:, Anaphylactic reaction (broad), Lack of efficacy/effect (narrow), Neuroleptic malignant syndrome (broad), Anticholinergic syndrome (broad), Acute central respiratory depression (broad), Pulmonary hypertension (broad), Cardiomyopathy (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Infective pneumonia (broad), Opportunistic infections (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-03-13
   Days after onset: 8
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? Yes, ? days
   Extended hospital stay? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions: Medical History/Concurrent Conditions: Diabetes; Hypertension; Oxygen saturation decreased
Allergies:
Diagnostic Lab Data: Test Name: saturation without oxygen; Test Result: 93 %; Test Date: 20210305; Test Name: Sars Cov-2 test; Result Unstructured Data: Test Result:positive
CDC Split Type: PLPFIZER INC2021293309

Write-up: fever; problem with breathing; Sars COV-2 test positive; the patient died; Sars COV-2 test positive; This is a spontaneous report from a contactable pharmacist. A male patient of an unspecified age received bnt162b2 (COMIRNATY), dose 1 via an unspecified route of administration on 19Feb2021 (Lot Number: EP9598) as SINGLE DOSE for COVID-19 immunisation. The second dose was scheduled for 12Mar2021 Medical history included arterial hypertension, diabetes treated with DL HG, respiratory efficiency, full contact, oxygen saturation 93%; all from an unknown date and unknown if ongoing. The patient''s concomitant medications were not reported. On 04Mar2021, the patient reported to the general physician due to high fever that has been going on for several days (the reporter doesn''t know when the fever started). General physician did not initiate any treatment, he referred the patient to the internal ward of the hospital. On 05Mar2021, the patient reported to the hospital where SARS COV-2 test for COVID 19 was performed - the result: positive, the test was performed at 20:59. The reporter gave the data from the discharge from this hospital: "patient with quarantine, headed by the general physician as a fever, claims he had not had a PRC swab before. A high fever for several days, the primary health care physician did not start any treatment. The patient was prescribed the following drugs: levoxa, pyralgina, berodual, neoparin, monitoring with the general physician and he was sent home. On 07Mar2021 in the morning, the patient had a problem with breathing, the patient was hit to the hospital in the infectious diseases ward. First, the patient was connected to oxygen. On 09Mar2021 patient was put on a respirator due to health deterioration. On 13Mar2021 the patient died. It was not reported if an autopsy was performed. The outcome of Sars COV-2 test positive, fever and problem with breathing was unknown.; Sender''s Comments: The causal relationship between BNT162B2 and the events drug ineffective and SARS-CoV-2 test positive, pyrexia, dyspnoea and patient death cannot be excluded as the information available in this report is limited and does not allow a medically meaningful assessment. This case will be reassessed once additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.; Reported Cause(s) of Death: the patient died


VAERS ID: 1133428 (history)  
Form: Version 2.0  
Age:   
Sex: Female  
Location: Foreign  
Vaccinated:2021-02-09
Onset:2021-02-17
   Days after vaccination:8
Submitted: 0000-00-00
Entered: 2021-03-25
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH EL0725 / 2 LA / OT

Administered by: Other       Purchased by: ?
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
SMQs:, Lack of efficacy/effect (narrow), Infective pneumonia (broad), Opportunistic infections (broad), COVID-19 (narrow)

Life Threatening? No
Birth Defect? No
Died? Yes
   Date died: 2021-02-20
   Days after onset: 3
Permanent Disability? No
Recovered? No
Office Visit? No
ER Visit? No
ER or Doctor Visit? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness:
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: Test Date: 20210217; Test Name: COVID-19 PCR test; Test Result: Positive
CDC Split Type: ITPFIZER INC2021297541

Write-up: Positive molecular swab; COVID-19/dyspnea; This is a spontaneous report from contactable physician downloaded from the Regulatory authority-WEB regulatory authority IT-MINISAL02-697591. A 98-years-old female patient received the first dose of bnt162b2 (COMIRNATY), via an unspecified route of administration on 19Jan2021 at single dose, and the second dose (Batch/Lot Number: EL0725; Expiration Date: 31Mar2021), via intramuscular administered in left arm on 09Feb2021 09:52 at 0.3 mL, single for COVID-19 vaccination. The patient medical history and concomitant medications were not reported. The patient experienced positive molecular swab on 17Feb2021, dyspnea from 20Feb2021, died hospitalized in hospital on 20Feb2021. The patient underwent lab tests and procedures which included COVID-19 PCR test: positive on 17Feb2021. The patient died on 20Feb2021. It was not reported if an autopsy was performed. Reporter comment: 1st DOSE TAKEN ON 19Jan2021. Positive molecular swab on 17Feb2021 Died hospitalized in hospital on 20Feb. Sender comment: 12Feb2021: contacted the reporter to request a clinical report of death.; Reported Cause(s) of Death: Positive molecular swab; COVID-19/dyspnea


Result pages: prev   14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32   next

New Search

Link To This Search Result:

https://medalerts.org/vaersdb/findfield.php?EVENTS=ON&PAGENO=23&ESORT=AGE&SYMPTOMS=COVID-19&VAX=COVID19&DIED=Yes


Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166